Scancell (LON:SCLP) Reaches New 52-Week High – What’s Next?

Scancell Holdings plc (LON:SCLP)’s share price reached a new 52-week high during trading on Wednesday. The company traded as high as GBX 89.50 and last traded at GBX 89.50, with a volume of 1,442,882 shares traded. The stock had previously closed at GBX 9.30.

Scancell Stock Up 862.4%

The firm has a market capitalization of £1.21 billion, a price-to-earnings ratio of -162.73 and a beta of 0.69. The company has a current ratio of 0.28, a quick ratio of 13.01 and a debt-to-equity ratio of -88.01. The firm has a 50 day moving average price of GBX 9.62 and a two-hundred day moving average price of GBX 13.86.

Scancell (LON:SCLP) last issued its earnings results on Friday, October 9th. The company reported GBX (1.73) earnings per share (EPS) for the quarter. Scancell had a positive return on equity of 128.87% and a negative net margin of 116.98%. On average, equities analysts expect that Scancell Holdings plc will post -2.54 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.